BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
Italian police hold suspected boss of Naples Mafia's Mazzarella Clan- Best Food Truck Cooking: Decision in favor of Your Number one!
- Brazil approves law strengthening protective measures for female victims of gender-based violence
- Progress Over Perfection: Lessons From Garment Factories Fighting Heat Stress
- Dark matter obeys gravity after all — could that rule out a 5th fundamental force in the universe?
- Woman leaves bachelorette trip after trusting her gut about sketchy men partying it up with friends
- Excelling at Cash The board: A Manual for Monetary Essentials
- Vote In favor of Your Favored Distributed computing Administration
- Native artists in Texas and Mexico shared their vision of the universe for 4,000 years, ancient murals suggest
